Overall summary of adverse events (treated set).

aPatients were randomised 2:2:1 to the tiotropium Respimat 5 μg, tiotropium Respimat 2.5 μg and placebo Respimat groups, respectively.bAs determined by the investigator.cElevation of aspartate aminotransferase and/or alanine aminotransferase ≥3 × upper limit of normal combined with elevated total bilirubin ≥2 × upper limit of normal at the same visit.dAsthma worsening.AE, adverse event.Overall summary of adverse events (treated set).a. 受试者按2:2:1的比例随机分配至噻托溴铵Respimat 5μg组、噻托溴铵Respimat 2.5μg组及安慰剂Respimat组。 b. 由研究者进行判定。 c. 同次就诊时，天冬氨酸氨基转移酶和/或丙氨酸氨基转移酶升高至正常上限3倍及以上，且总胆红素升高至正常上限2倍及以上。 d. 哮喘恶化。 不良事件（Adverse Event, AE）。 不良事件总体总结（治疗集）。